A Multifactor Approach to Mild Cognitive Impairment

 

 Buy Article Permissions and Reprints

Abstract

Mild cognitive impairment (MCI) represents an intermediate stage between normal cognition and dementia. Individuals with MCI are at increased risk of conversion to dementia, and the rate of progression of MCI to dementia is dependent on age, gender, and education. MCI may be diagnosed using neuropsychological criteria using cut-offs representing decrements in cognition, or using criteria to assess for a decline in functional status. The ability to determine the status of dementia-related biomarkers has allowed for better staging and prognostication in different forms of MCI. MCI is now recognized as a significant target stage for future therapies. These future therapies aim to reduce the rate of conversion of individuals with MCI to dementia. In this article, we review different conceptions of MCI, the diagnosis and prognostication of MCI, and presently available management approaches for this condition.

• References

• 1 Lopez OL. Mild cognitive impairment. Continuum (Minneap Minn) 2013; 19 (2 Dementia): 411-424
  PubMedGoogle Scholar
• 2 Prestia A, Caroli A, van der Flier WM. , et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 2013; 80 (11) 1048-1056
  CrossrefPubMedGoogle Scholar
• 3 Petersen RC, Lopez O, Armstrong MJ. , et al. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90 (03) 126-135
  CrossrefPubMedGoogle Scholar
• 4 Suzuki T, Shimada H, Makizako H. , et al. A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment. PLoS One 2013; 8 (04) e61483
  CrossrefPubMedGoogle Scholar
• 5 Cheng YW, Chen TF, Chiu MJ. From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution. Neuropsychiatr Dis Treat 2017; 13: 491-498
  CrossrefPubMedGoogle Scholar
• 6 Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA 2014; 312 (23) 2551-2561
  CrossrefPubMedGoogle Scholar
• 7 Heinik J. V. A. Kral, the Montreal Hebrew Old People's Home, and benign senescent forgetfulness. Hist Psychiatry 2006; 17 (67 Pt 3): 313-332
  CrossrefPubMedGoogle Scholar
• 8 Golomb J, Kluger A, Ferris SH. Mild cognitive impairment: historical development and summary of research. Dialogues Clin Neurosci 2004; 6 (04) 351-367
  CrossrefPubMedGoogle Scholar
• 9 Resiberg B, Ferris SH, de Leon MJ. , et al. Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment (AAMI) and primary degenerative dementia of the Alzheimer type. Drug Dev Res 1988; 15: 101-114
  CrossrefPubMedGoogle Scholar
• 10 Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43 (11) 2412-2414
  PubMedGoogle Scholar
• 11 Petersen RC, Smith GE, Ivnik RJ. , et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273 (16) 1274-1278
  CrossrefPubMedGoogle Scholar
• 12 Nasreddine ZS, Phillips NA, Bédirian V. , et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53 (04) 695-699
  CrossrefPubMedGoogle Scholar
• 13 Ciesielska N, Sokołowski R, Mazur E, Podhorecka M, Polak-Szabela A, Kędziora-Kornatowska K. Is the Montreal Cognitive Assessment (MoCA) test better suited than the Mini-Mental State Examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis. Psychiatr Pol 2016; 50 (05) 1039-1052
  CrossrefPubMedGoogle Scholar
• 14 Chu LW, Ng KH, Law AC, Lee AM, Kwan F. Validity of the Cantonese Chinese Montreal Cognitive Assessment in Southern Chinese. Geriatr Gerontol Int 2015; 15 (01) 96-103
  CrossrefPubMedGoogle Scholar
• 15 Gagnon G, Hansen KT, Woolmore-Goodwin S. , et al. Correcting the MoCA for education: effect on sensitivity. Can J Neurol Sci 2013; 40 (05) 678-683
  PubMedGoogle Scholar
• 16 Espino DV, Lichtenstein MJ, Palmer RF, Hazuda HP. Ethnic differences in mini-mental state examination (MMSE) scores: where you live makes a difference. J Am Geriatr Soc 2001; 49 (05) 538-548
  CrossrefPubMedGoogle Scholar
• 17 Matallana D, de Santacruz C, Cano C. , et al. The relationship between education level and mini-mental state examination domains among older Mexican Americans. J Geriatr Psychiatry Neurol 2011; 24 (01) 9-18
  CrossrefPubMedGoogle Scholar
• 18 Jak AJ, Bondi MW, Delano-Wood L. , et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. Am J Geriatr Psychiatry 2009; 17 (05) 368-375
  CrossrefPubMedGoogle Scholar
• 19 Petersen RC. Mild cognitive impairment. Continuum (Minneap Minn) 2016; 22 (2 Dementia): 404-418
  PubMedGoogle Scholar
• 20 Ganguli M, Fu B, Snitz BE, Hughes TF, Chang CC. Mild cognitive impairment: incidence and vascular risk factors in a population-based cohort. Neurology 2013; 80 (23) 2112-2120
  CrossrefPubMedGoogle Scholar
• 21 Sachdev PS, Lipnicki DM, Crawford J. , et al; Sydney Memory, Ageing Study Team. Factors predicting reversion from mild cognitive impairment to normal cognitive functioning: a population-based study. PLoS One 2013; 8 (03) e59649
  CrossrefPubMedGoogle Scholar
• 22 Koepsell TD, Monsell SE. Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis. Neurology 2012; 79 (15) 1591-1598
  CrossrefPubMedGoogle Scholar
• 23 Clem MA, Holliday RP, Pandya S, Hynan LS, Lacritz LH, Woon FL. Predictors that a diagnosis of mild cognitive impairment will remain stable 3 years later. Cogn Behav Neurol 2017; 30 (01) 8-15
  CrossrefPubMedGoogle Scholar
• 24 Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56 (03) 303-308
  CrossrefPubMedGoogle Scholar
• 25 Li JQ, Tan L, Wang HF. , et al. Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis of cohort studies. J Neurol Neurosurg Psychiatry 2016; 87 (05) 476-484
  CrossrefPubMedGoogle Scholar
• 26 Yarnall AJ, Rochester L, Burn DJ. Mild cognitive impairment in Parkinson's disease. Age Ageing 2013; 42 (05) 567-576
  CrossrefPubMedGoogle Scholar
• 27 Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol 2009; 66 (09) 1151-1157
  PubMedGoogle Scholar
• 28 Jack CJr, Knopman DS, Jagust WJ. , et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12 (02) 207-216
  CrossrefPubMedGoogle Scholar
• 29 Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med 2011; 364 (23) 2227-2234
  CrossrefPubMedGoogle Scholar
• 30 Jack Jr CR, Bennett DA, Blennow K. , et al; Contributors. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018; 14 (04) 535-562
  CrossrefPubMedGoogle Scholar
• 31 Monastero R, Cicero CE, Baschi R. , et al. Mild cognitive impairment in Parkinson's disease: the Parkinson's disease cognitive study (PACOS). J Neurol 2018; 265 (05) 1050-1058
  CrossrefPubMedGoogle Scholar
• 32 Meireles J, Massano J. Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management. Front Neurol 2012; 3: 88
  PubMedGoogle Scholar
• 33 Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008; 70 (13) 1017-1022
  CrossrefPubMedGoogle Scholar
• 34 Williams-Gray CH, Mason SL, Evans JR. , et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013; 84 (11) 1258-1264
  CrossrefPubMedGoogle Scholar
• 35 Levy G, Tang MX, Louis ED. , et al. The association of incident dementia with mortality in PD. Neurology 2002; 59 (11) 1708-1713
  CrossrefPubMedGoogle Scholar
• 36 Lo RY, Tanner CM, Albers KB. , et al. Clinical features in early Parkinson disease and survival. Arch Neurol 2009; 66 (11) 1353-1358
  PubMedGoogle Scholar
• 37 Litvan I, Goldman JG, Tröster AI. , et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27 (03) 349-356
  CrossrefPubMedGoogle Scholar
• 38 Smith E. Vascular cognitive impairment. Continuum (Minneap Minn) 2016; 22 (2 Dementia): 490-509
  PubMedGoogle Scholar
• 39 Mijajlović MD, Pavlović A, Brainin M. , et al. Post-stroke dementia - a comprehensive review. BMC Med 2017; 15 (01) 11
  CrossrefPubMedGoogle Scholar
• 40 Wardlaw JM, Smith EE, Biessels GJ. , et al; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12 (08) 822-838
  CrossrefPubMedGoogle Scholar
• 41 Sachdev P, Kalaria R, O'Brien J. , et al; Internationlal Society for Vascular Behavioral and Cognitive Disorders. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord 2014; 28 (03) 206-218
  CrossrefPubMedGoogle Scholar
• 42 Fink HA, Jutkowitz E, McCarten JR. , et al. Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review. Ann Intern Med 2018; 168 (01) 39-51
  CrossrefPubMedGoogle Scholar
• 43 Kernan WN, Ovbiagele B, Black HR. , et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45 (07) 2160-2236
  CrossrefPubMedGoogle Scholar
• 44 Brasure M, Desai P, Davila H. , et al. Physical activity interventions in preventing cognitive decline and Alzheimer-type dementia: a systematic review. Ann Intern Med 2018; 168 (01) 30-38
  CrossrefPubMedGoogle Scholar
• 45 Butler M, Nelson VA, Davila H. , et al. Over-the-counter supplement interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review. Ann Intern Med 2018; 168 (01) 52-62
  CrossrefPubMedGoogle Scholar
• 46 Butler M, McCreedy E, Nelson VA. , et al. Does cognitive training prevent cognitive decline?: a systematic review. Ann Intern Med 2018; 168 (01) 63-68
  CrossrefPubMedGoogle Scholar
• 47 Bartels C, Wagner M, Wolfsgruber S, Ehrenreich H, Schneider A. ; Alzheimer's Disease Neuroimaging Initiative. Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer's dementia in individuals with previous depression. Am J Psychiatry 2018; 175 (03) 232-241
  CrossrefPubMedGoogle Scholar
• 48 Cooper C, Li R, Lyketsos C, Livingston G. Treatment for mild cognitive impairment: systematic review. Br J Psychiatry 2013; 203 (03) 255-264
  CrossrefPubMedGoogle Scholar
• 49 Scheltens P, Leys D, Barkhof F. , et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992; 55 (10) 967-972
  CrossrefPubMedGoogle Scholar
• 50 Aisen PS, Petersen RC, Donohue MC. , et al; Alzheimer's Disease Neuroimaging Initiative. Clinical core of the Alzheimer's disease neuroimaging initiative: progress and plans. Alzheimers Dement 2010; 6 (03) 239-246
  CrossrefPubMedGoogle Scholar
• 51 Jessen F, Wolfsgruber S, Wiese B. , et al; German Study on Aging, Cognition and Dementia in Primary Care Patients. AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimers Dement 2014; 10 (01) 76-83
  CrossrefPubMedGoogle Scholar
• 52 Verghese J, Wang C, Lipton RB, Holtzer R. Motoric cognitive risk syndrome and the risk of dementia. J Gerontol A Biol Sci Med Sci 2013; 68 (04) 412-418
  CrossrefPubMedGoogle Scholar
• 53 Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ, Buschke H. Abnormality of gait as a predictor of non-Alzheimer's dementia. N Engl J Med 2002; 347 (22) 1761-1768
  CrossrefPubMedGoogle Scholar
• 54 Verghese J, Wang C, Lipton RB, Holtzer R, Xue X. Quantitative gait dysfunction and risk of cognitive decline and dementia. J Neurol Neurosurg Psychiatry 2007; 78 (09) 929-935
  CrossrefPubMedGoogle Scholar
• 55 Verghese J, Robbins M, Holtzer R. , et al. Gait dysfunction in mild cognitive impairment syndromes. J Am Geriatr Soc 2008; 56 (07) 1244-1251
  CrossrefPubMedGoogle Scholar
• 56 Ismail Z, Agüera-Ortiz L, Brodaty H. , et al; NPS Professional Interest Area of the International Society of to Advance Alzheimer's Research and Treatment (NPS-PIA of ISTAART). The Mild Behavioral Impairment Checklist (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations. J Alzheimers Dis 2017; 56 (03) 929-938
  CrossrefPubMedGoogle Scholar
• 57 Velickaite V, Ferreira D, Cavallin L. , et al. Medial temporal lobe atrophy ratings in a large 75-year-old population-based cohort: gender-corrected and education-corrected normative data. Eur Radiol. 2018; Apr; 28 (04) 1739-1747
  CrossrefPubMedGoogle Scholar